http://www.hardmanandco.com/Research/Alliance_June2005.pdf


Web Site : http://www.alliancepharma.co.uk

http://www.hemscott.com/hstoday/Focus_2005/Alliance%20Pharma_1205_2005.htm

Hardmans late June 2005 update

Fair value at 30p

http://www.hardmanandco.com/Research/Alliance_June2005.pdf

Shares in issue: 147.4m 1p Ords

Major Shareholders Amount % Holding

John Dawson 46,685,079 31.68
Stella Anne Dawson 15,576,323 10.57
RAB Capital PLC 8.80
Chase Nominees Limited 9,164,675 6.22
Aviva PLC 6.00
F&C Asset Management PLC 4.90
Anthony Richard Booley 6,710,723 4.55
Fidelity Management & Research Company 6,500,000 4.41
Artemis Inv Mgmt Ltd 4.10

Nigel Wray 5,655,407 3.84

Morstan Nominees Ltd 5,532,399 3.75

-------------------------------------

Alliance Pharma says Nigel Wray buys shares

LONDON (AFX) - Alliance Pharma PLC said Nigel Wray has acquired 3,500,000
ordinary shares in the company, representing 2.38 pct and now holds 5,655,407
shares, representing 3.84 pct.

newsdesk@afxnews.com slm/ Nov 2004

Always keep an eye on what NW buys into..........

Alliance Pharma PLC
28 February 2005

For immediate release: 28th February 2005





ALLIANCE PHARMA PLC

('Alliance' or 'the Company')

DIRECTOR'S SHARE DEALING



On 22nd February 2005, Paul Ransom, a non-executive Director of Alliance Pharma
plc, purchased 48,000 shares at 15.5p. The purchase represents the total amount
of his holding in the Company.



- ends -





For further information please contacts:



Alliance Pharma plc
John Dawson, CEO
01249 466966



Beattie Financial
Mike Wort/John Moriarty
020 7398 3300




This information is provided by RNS
The company news service from the London Stock Exchange

Take a read of this

"http://miranda.hemscott.com/ir/aph/docs/InstitutionsPresentation.ppt#256,1,Alliance Pharma plc Project Byron"

PapalPower: Thanks - apppreciated yout posting - my kind of recovery stock. RAB involvement jumped out
at me - shrewd guys those.
sd.

Glad I'm just watching. Down over 6% today on a 100k sell.
But my gambler's instinct tells me it's near the bottom where we bottom fishers love to feed.
sd.

Welcome squidd, add into it that Nigel Wray is there too, something is happening - even more so by the complete quiet being kept around it at the moment.

Prelim is expected around the 12th May, have to watch for any large buys going on April onwards.

squidd, if you like being a bottom feeder, take a look at OSH, its a high risk, potential high reward one, however, its a recession free industry and one which will continue to grow. The previous CEO messed up a bit and the price got hammered, new CEO was in a month before the last results and I am expecting improved profits, restructuring done and a very positive outlook come reporting time. If you like RAB and their investments, take a look at the shareholders for TAG, expect things to move on that one around June time.

Good news today.

Alliance Pharma PLC
16 March 2005

For immediate release: 16th March 2005



ALLIANCE PHARMA PLC
('Alliance' or 'the Company')


PRE-CLOSE TRADING UPDATE


Alliance Pharma plc, the emerging speciality pharmaceutical company, is pleased
to provide a trading update prior to entering its closed period for the full
year to 28 February 2005.


Profits are anticipated to be within the range of analysts' expectations. Sales
for the year ending 28 February 2005 are expected to be in the region of 11.8
million, up from 10.4 million last year.


Trading performance is showing sales growth of 13%, over the same period in the
previous financial year. Growth on a like-for-like basis was 7%, with a further
6% growth being achieved through acquisitions.


The company made two acquisitions in November 2004: Forceval, a prescription
multivitamin and mineral supplement that is licensed and reimbursed on the NHS
in the UK and sold to various other overseas markets via distributors, and
Periostat, a pharmaceutical treatment for periodontitis, for the UK and all the
other countries in the European Union as well as Switzerland, Israel, South
Africa, Australia and New Zealand.


In the four months since the acquisitions of Forceval and Periostat, the Company
is pleased to announce that sales of both products have been in line with
expectations. Since acquisition, Alliance Pharma has strengthened the
relationships with the international distributors and the order book for
international sales going forward is in line with its expectations. To drive
Forceval's international expansion, the Company is looking forward to announcing
the appointment of a Head of the International Division within the next few
weeks. Similarly, to start to unlock the potential within Periostat, the
appointment of the Head of the Dental Division will be announced shortly


The registration trial programme for Alliance's development drug, misoprostol
for the induction of labour (APL202), which commenced in January, is continuing
according to plan. Approvals are expected soon to permit the trials programme
for Melatonin for sleep disorders (APL 510) to commence.


John Dawson, CEO of Alliance Pharma, commented:


'2004 has been another important year for Alliance. We have continued our
growth and further strengthened our portfolio. Periostat, in particular, has
tremendous growth potential. Good progress has also been made on our
development projects, adding greatly to our mid-term prospects'.


Preliminary results for the 12 month period to 28 February 2005 will be
announced on Thursday 12th May 2005.


- ends -


For further information:



Alliance Pharma plc
John Dawson, CEO
01249 466966


Beattie Financial
John Moriarty
020 7398 3300






This information is provided by RNS
The company news service from the London Stock Exchange

Periostat (mentioned in the trading statement) is one that is going to really boost the P+L account mid term.


Enzyme suppressor as a novel adjunctive therapy for serious gum disease (periodontitis)
Developed by CollaGenex (US)
Sales currently 347k (281k UK)
High growth potential UK sales currently based on 6,000 patients from pool of 3.2m
US sales $45m after 5 yrs
Alliance has agreed contract for EU, Switzerland, Israel, Australia, NZ and S. Africa

As RAB Capital is into APH


Friday 18th March LONDON - Hedge fund manager Rab Capital saw a 65% rise in pre-tax profit and a 75% increase assets under management last year with another surge in January and February of this year.

Pre-tax profit was 17.5m compared with 10.6m last time, a 13-month period to December 2003.

Assets under management by Rab rose to $1.75bn compared to $1.02bn previously, but are now believed to be through the $2bn barrier following a 25% rise in the past two months.

"Performance for the first two months of 2005 has significantly exceeded the same period of 2004 and assets under management have grown strongly since the year end," said the company.

Sales revenue of 36.2m came in 56% higher than 2003. Management fees went up from 6.6m in 2003 to 10.1m in 2004.

The dividend for the year doubles to 0.50p from 0.25p in 2003.

PpP: Having looked at APH, I feel no urge to climb aboard at present. It has a bland website, miniscule director buys, low traded volumes and no sign yet of recovery on the charts. TED looks much more promising on all these counts and have recently bought them. However, with the heavyweight institutional support for APH that you point out, they are now on my watch list.
OSH came up on my radar with modest director buys, but so far they seem to be stuck in a downtrend; and I can't find a proper website for them, only something about dentistry, so will contine to watch.
sd.

squidd : At present it appears nothing exciting at APH short term, I shall be looking for any more institutional support that comes in short term, and then the news on results. APH looks attractive presently in the mid term, but as we all know, anything can happen, I would not expect any short term downside or bad news - so even holding in the short term "can" only give upside on good news.

OSH web site is www.oasis-healthcare.com. This is a recovery play. High turnover and high debt (debt is due to building the group) - the debt is "not" a worry IMO owing to the business plan. If the results are good, this will rebound strongly. The new man in charge, Stephen Lambert, in for a year now, should have turned it around - so potential large bounce on the results. OSH are trying to do the same with dentistry as Boots and the like did with pharmacy - take a fragmented market and turn it into a large group. Its a growing market and recession proof. Just need to wait and see if Lambert has made the changes needed, after the last man messed up a bit. IMO, turn around will be stated soon.

PpP: Wakened by the sweet sound of much needed rain. Thanks for updated info on APH and OSH; both high on my watch list.
Have you looked at my earlier pharma recovery stocks - TED and post-crash ELA.
sQd.

Alliance Pharma PLC
30 March 2005

For immediate release: 30 March 2005





ALLIANCE PHARMA PLC

('Alliance' or 'the Company')


SHAREHOLDINGS IN COMPANY



Fidelity acquire an additional 3,700,000 ordinary shares





On 30th March 2005 the Company was notified by Fidelity Investments, ('FMR Corp
'), that it had increased its shareholding by 3,700,000 shares. The notifiable
interest is with FMR Corp and Fidelity International Limited (FIL) which also
comprises the notifiable interest of Mr Edward C Johnson 3d, a principal
shareholder of FMR Corp and Fidelity International Limited. The shares held
currently are as follows:


Shares Held Management Company Nominee/Registered Name
240,500 FIL Brown Brothers Harriman Ltd LUX
9,959,500 FMRCO Mellon Bank
TOTAL 10,200,000



The total percentage shareholding of FMR Corp and Fidelity International Limited
is now 9.43%

Prelims est 12th May.

We have a buyer it seems, looking at trade values and timings.

16:38:44 13-Apr-2005 13.00 50,000 6,500.00 Single protected transaction
16:38:44 14-Apr-2005 13.00 50,000 6,500.00 Single protected transaction

Same time to the second.

Another 50K today at 16:38 and 44 seconds ?

13M Cross Trade today (9% of all shares)

Alliance Pharma PLC
09 May 2005


For immediate release 9 May 2005

ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Announces Co-Promotion Agreement with OralDent Ltd

Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce a co-promotion agreement with OralDent Ltd ('OralDent'),
a privately owned dental products company, for the UK marketing and distribution of Periostat(R), a prescription medicine for the treatment of the severe gum disease periodontitis.

Periostat is a major growth opportunity for Alliance Pharma and this agreement
with OralDent marks the first step in the roll-out of the product across the
territories for which the Company holds marketing rights. Alliance Pharma
acquired the rights in November 2004 from CollaGenex International Ltd, part of
CollaGenex Pharmaceuticals Inc (Nasdaq: CGPI), for the territories of the
enlarged European Union, Switzerland, Israel, Australia, New Zealand and South
Africa.

The international roll-out of the product will be led by a senior international
manager, who was recently appointed to head the Company's newly formed
International Division.

OralDent focuses on promoting products to private and NHS dentists in the UK via a field sales force, a tele-sales operation and an internet portal. Alliance Pharma will contribute resources to enable OralDent to increase the size of its sales force to maximise the sales of Periostat. Alliance Pharma will recognise the Periostat sales and OralDent will receive sales-based royalties on a sliding scale between 5%per cent and 15% per cent.

Periostat is the first and only approved oral pharmaceutical product for the
adjunctive treatment of adult periodontal disease (periodontitis) by the
suppression of those enzymes that destroy periodontal support tissues. Periostat is included in the Secretary of State for Health's list for dental prescribing and is listed on the UK's Dental Practitioners' Formulary. Periodontitis is estimated to affect 11 per cent of the adult population in the UK.

Commenting, John Dawson, Alliance Pharma's Chief Executive, said: 'Periostat is
a major growth opportunity for the Company and this UK co-promotion agreement is an important first step in maximising the potential of the product. OralDent has a particularly strong franchise in the UK dental market and we look forward to a successful collaboration with them.'

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

And some strong buying yesterday.

PpP: I see our favourite pharma's continue to storm uphill and thanks to a takeover rumour today, ELA takes the lead. Nice to see some splashes of blue inside, with the bluebells outside.
sd.